ELV Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Elevance Health Inc (ELV) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has demonstrated strong financial performance in its latest quarter and analysts remain broadly optimistic about the healthcare sector, the ongoing investigation, recent sanctions, and hedge fund selling create uncertainties. The technical indicators suggest a neutral trend, and there are no strong proprietary trading signals or recent congress trading data to support immediate action. Holding the stock or waiting for further clarity on the investigation and regulatory issues may be a more prudent approach.
The MACD is positive at 2.74, indicating bullish momentum, but it is contracting. RSI at 65.008 is neutral, and moving averages are converging, suggesting no clear trend. The stock is trading near its resistance level (R1: 320.506), with key support at 309.841. The technical indicators suggest a neutral to slightly bullish trend but lack strong conviction for a buy.
Strong financial performance in Q4 2025, with revenue up 9.47% YoY, net income up 30.86% YoY, and EPS up 36.46% YoY.
Analysts remain broadly optimistic about the healthcare sector, citing strong demand trends and favorable reimbursement policies.
Insider buying has increased significantly by 132.13% over the last month.
Ongoing investigation for potential violations of federal securities laws involving senior management misconduct.
Recent sanctions from CMS suspending enrollment of Medicare beneficiaries in certain plans.
Hedge funds have increased selling by 135.25% over the last quarter.
Recent price target reductions by multiple analysts, reflecting concerns about future guidance and regulatory risks.
In Q4 2025, Elevance Health reported strong financial results: revenue increased by 9.47% YoY to $49.75 billion, net income rose by 30.86% YoY to $547 million, and EPS grew by 36.46% YoY to 2.47. These results indicate robust growth and profitability.
Analysts have mixed views: Truist maintains a Buy rating with a reduced price target of $375, citing strong sector fundamentals. Evercore ISI initiated coverage with an In Line rating and a $345 price target, noting resilient earnings but potential downside risks. BofA raised its price target to $405 but kept a Neutral rating. Several other analysts have lowered price targets, reflecting regulatory concerns and softer guidance for 2026 and beyond.
